Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Buy
60
TMDX Quote, Financials, Valuation and Earnings
Last price:
$76.41
Seasonality move
:
31.79%
Day range:
$72.78 - $78.71
52-week range:
$55.00 - $177.37
Dividend yield:
0%
P/E ratio:
74.66x
P/S ratio:
6.01x
P/B ratio:
11.10x
Volume:
2.1M
Avg. volume:
1.1M
1-year change:
-19.12%
Market cap:
$2.5B
Revenue:
$441.5M
EPS (TTM):
$1.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TMDX
TransMedics Group
|
$123.4M | $0.24 | 27.41% | -31.06% | $102.86 |
|
AXGN
Axogen
|
$48.3M | $0.02 | 16.84% | -76% | $25.71 |
|
ELMD
Electromed
|
$15.8M | -- | 13.91% | -- | $37.00 |
|
IRIX
IRIDEX
|
$12.8M | -$0.12 | -2.72% | -18.18% | -- |
|
MYO
Myomo
|
$9.2M | -$0.08 | 145.61% | -24% | $9.25 |
|
STXS
Stereotaxis
|
$6.9M | -$0.07 | -0.07% | -20.83% | $4.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TMDX
TransMedics Group
|
$75.41 | $102.86 | $2.5B | 74.66x | $0.00 | 0% | 6.01x |
|
AXGN
Axogen
|
$16.76 | $25.71 | $743.2M | -- | $0.00 | 0% | 3.96x |
|
ELMD
Electromed
|
$23.53 | $37.00 | $201.3M | 31.37x | $0.00 | 0% | 3.53x |
|
IRIX
IRIDEX
|
$0.94 | -- | $15.6M | -- | $0.00 | 0% | 0.32x |
|
MYO
Myomo
|
$4.68 | $9.25 | $160.9M | -- | $0.00 | 0% | 5.43x |
|
STXS
Stereotaxis
|
$1.75 | $4.50 | $150.5M | -- | $0.00 | 0% | 5.54x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TMDX
TransMedics Group
|
69.02% | 2.597 | 24.3% | 7.25x |
|
AXGN
Axogen
|
31.37% | 1.669 | 6.53% | 1.88x |
|
ELMD
Electromed
|
-- | 1.939 | -- | 4.68x |
|
IRIX
IRIDEX
|
51.25% | 1.717 | 9.47% | 0.73x |
|
MYO
Myomo
|
-- | 2.090 | -- | 2.82x |
|
STXS
Stereotaxis
|
-- | 1.683 | -- | 0.74x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TMDX
TransMedics Group
|
$72M | $8.6M | 5.12% | 19.17% | 8.68% | $6.1M |
|
AXGN
Axogen
|
$37.6M | $2M | -6.89% | -10.21% | 4.56% | $7.9M |
|
ELMD
Electromed
|
$12.6M | $2.5M | 15.91% | 15.91% | 15.64% | $2.9M |
|
IRIX
IRIDEX
|
$4.3M | -$1.9M | -146.36% | -157.91% | -16.15% | -$3.1M |
|
MYO
Myomo
|
$8.6M | -$245.3K | -48.64% | -48.64% | -2.03% | $2.5M |
|
STXS
Stereotaxis
|
$3.2M | -$7.6M | -139.2% | -139.2% | -120.3% | $1.3M |
TransMedics Group vs. Competitors
-
Which has Higher Returns TMDX or AXGN?
Axogen has a net margin of 5.64% compared to TransMedics Group's net margin of 0.91%. TransMedics Group's return on equity of 19.17% beat Axogen's return on equity of -10.21%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M AXGNAxogen76.06% $0.01 $151.4M -
What do Analysts Say About TMDX or AXGN?
TransMedics Group has a consensus price target of $102.86, signalling upside risk potential of 36.4%. On the other hand Axogen has an analysts' consensus of $25.71 which suggests that it could grow by 53.43%. Given that Axogen has higher upside potential than TransMedics Group, analysts believe Axogen is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 AXGNAxogen5 0 0 -
Is TMDX or AXGN More Risky?
TransMedics Group has a beta of 2.138, which suggesting that the stock is 113.849% more volatile than S&P 500. In comparison Axogen has a beta of 0.995, suggesting its less volatile than the S&P 500 by 0.462%.
-
Which is a Better Dividend Stock TMDX or AXGN?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or AXGN?
TransMedics Group quarterly revenues are $121.6M, which are larger than Axogen quarterly revenues of $49.4M. TransMedics Group's net income of $6.9M is higher than Axogen's net income of $450K. Notably, TransMedics Group's price-to-earnings ratio is 74.66x while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 6.01x versus 3.96x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group6.01x 74.66x $121.6M $6.9M AXGNAxogen3.96x -- $49.4M $450K
-
Which has Higher Returns TMDX or ELMD?
Electromed has a net margin of 5.64% compared to TransMedics Group's net margin of 12.11%. TransMedics Group's return on equity of 19.17% beat Electromed's return on equity of 15.91%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M ELMDElectromed77.68% $0.22 $43.6M -
What do Analysts Say About TMDX or ELMD?
TransMedics Group has a consensus price target of $102.86, signalling upside risk potential of 36.4%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 57.25%. Given that Electromed has higher upside potential than TransMedics Group, analysts believe Electromed is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 ELMDElectromed2 0 0 -
Is TMDX or ELMD More Risky?
TransMedics Group has a beta of 2.138, which suggesting that the stock is 113.849% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.
-
Which is a Better Dividend Stock TMDX or ELMD?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or ELMD?
TransMedics Group quarterly revenues are $121.6M, which are larger than Electromed quarterly revenues of $16.3M. TransMedics Group's net income of $6.9M is higher than Electromed's net income of $2M. Notably, TransMedics Group's price-to-earnings ratio is 74.66x while Electromed's PE ratio is 31.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 6.01x versus 3.53x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group6.01x 74.66x $121.6M $6.9M ELMDElectromed3.53x 31.37x $16.3M $2M
-
Which has Higher Returns TMDX or IRIX?
IRIDEX has a net margin of 5.64% compared to TransMedics Group's net margin of -16.69%. TransMedics Group's return on equity of 19.17% beat IRIDEX's return on equity of -157.91%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M IRIXIRIDEX37.33% -$0.12 $5.4M -
What do Analysts Say About TMDX or IRIX?
TransMedics Group has a consensus price target of $102.86, signalling upside risk potential of 36.4%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 112.61%. Given that IRIDEX has higher upside potential than TransMedics Group, analysts believe IRIDEX is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 IRIXIRIDEX0 0 0 -
Is TMDX or IRIX More Risky?
TransMedics Group has a beta of 2.138, which suggesting that the stock is 113.849% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.737, suggesting its less volatile than the S&P 500 by 26.316%.
-
Which is a Better Dividend Stock TMDX or IRIX?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or IRIX?
TransMedics Group quarterly revenues are $121.6M, which are larger than IRIDEX quarterly revenues of $11.6M. TransMedics Group's net income of $6.9M is higher than IRIDEX's net income of -$1.9M. Notably, TransMedics Group's price-to-earnings ratio is 74.66x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 6.01x versus 0.32x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group6.01x 74.66x $121.6M $6.9M IRIXIRIDEX0.32x -- $11.6M -$1.9M
-
Which has Higher Returns TMDX or MYO?
Myomo has a net margin of 5.64% compared to TransMedics Group's net margin of -2.16%. TransMedics Group's return on equity of 19.17% beat Myomo's return on equity of -48.64%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M MYOMyomo71.39% -$0.01 $24.7M -
What do Analysts Say About TMDX or MYO?
TransMedics Group has a consensus price target of $102.86, signalling upside risk potential of 36.4%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 97.65%. Given that Myomo has higher upside potential than TransMedics Group, analysts believe Myomo is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 MYOMyomo3 0 0 -
Is TMDX or MYO More Risky?
TransMedics Group has a beta of 2.138, which suggesting that the stock is 113.849% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.
-
Which is a Better Dividend Stock TMDX or MYO?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or MYO?
TransMedics Group quarterly revenues are $121.6M, which are larger than Myomo quarterly revenues of $12.1M. TransMedics Group's net income of $6.9M is higher than Myomo's net income of -$260.1K. Notably, TransMedics Group's price-to-earnings ratio is 74.66x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 6.01x versus 5.43x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group6.01x 74.66x $121.6M $6.9M MYOMyomo5.43x -- $12.1M -$260.1K
-
Which has Higher Returns TMDX or STXS?
Stereotaxis has a net margin of 5.64% compared to TransMedics Group's net margin of -118.53%. TransMedics Group's return on equity of 19.17% beat Stereotaxis's return on equity of -139.2%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M STXSStereotaxis50.73% -$0.09 $11.4M -
What do Analysts Say About TMDX or STXS?
TransMedics Group has a consensus price target of $102.86, signalling upside risk potential of 36.4%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 157.14%. Given that Stereotaxis has higher upside potential than TransMedics Group, analysts believe Stereotaxis is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 STXSStereotaxis2 0 0 -
Is TMDX or STXS More Risky?
TransMedics Group has a beta of 2.138, which suggesting that the stock is 113.849% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.
-
Which is a Better Dividend Stock TMDX or STXS?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or STXS?
TransMedics Group quarterly revenues are $121.6M, which are larger than Stereotaxis quarterly revenues of $6.3M. TransMedics Group's net income of $6.9M is higher than Stereotaxis's net income of -$7.5M. Notably, TransMedics Group's price-to-earnings ratio is 74.66x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 6.01x versus 5.54x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group6.01x 74.66x $121.6M $6.9M STXSStereotaxis5.54x -- $6.3M -$7.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Archer Aviation a Buy, Sell or Hold?
Vertical takeoff and landing (eVTOL) aircraft sound futuristic but that’s…
Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
Stock Ideas
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 31x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
18
BULZ alert for Apr 11
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 15.35% over the past day.
Sell
31
TECS alert for Apr 10
Direxion Daily Technology Bear 3x Shares [TECS] is up 12.66% over the past day.
Sell
48
FNGA alert for Apr 10
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 13.3% over the past day.
